Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1A Dose Escalation Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1A Dose Escalation Study of LP-184 in Patients With Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irofulven (Primary)
  • Indications Bladder cancer; Brain cancer; Brain metastases; Glioblastoma; Glioma; Lung cancer; Pancreatic cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Lantern Pharma

    • Most Recent Events

    • 07 Nov 2024 According to Lantern Pharma media release, the company announced enrollment projected to complete this year and initial safety and molecular correlation data expected by year-end 2024 or early 2025
    • 23 Sep 2024 According to Lantern Pharma media release, based on the results and findings from this clinical trial and other collaborative studies, the company will plan and potentially develop future clinical trials for specific pediatric patients in ATRT, MRT, RMS and Hepatoblastoma. The company anticipates enrolling 50 to 60 patients across a wide range of solid tumors in this trial.
    • 09 May 2024 According to Lantern Pharma media release, company has submitted a dose optimization and expansion protocol to the FDA related to LP-184 in non-CNS solid tumors, including TNBC with DDR alterations. Additionally, the company in collaboration with Starlight Therapeutics, has also submitted to the FDA a dose optimization and expansion protocol in recurrent IDH wild-type high grade gliomas

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top